Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
Terminal disease Clinical criteria: The treatment must be for the short-term, AND Patient must be receiving palliative care.
Refractory phobic or anxiety states Clinical criteria: The treatment must be for the short-term.
“Flunitrazepam is a member of the benzodiazepine group of drugs and is closely related to nitrazepam, flurazepam and clonazepam. It has marked sedative and hypnotic properties with a rapid onset of action.”
“Following intravenous administration, the elimination half-life for flunitrazepam is 20 to 30 hours, 10 to 16 hours for 7-amino-flunitrazepam and 23 to 33 hours for N-desmethyl-flunitrazepam.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Flunitrazepam undergoes oxidative metabolism, and consequently may interact with disulfiram or cimetidine, resulting in increased plasma levels of flunitrazepam.”